# OnCo record rasburicase (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/rasburicase/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "rasburicase" ;
  schema:name "Rasburicase"@en ;
  schema:alternateName "Fasturtec"@en, "Recombinant urate oxidase"@en, "Elitek" ;
  schema:description "Rasburicase (Elitek) is an enzyme infusion that rapidly dissolves the uric acid released when large numbers of leukaemia or lymphoma cells die at the start of treatment, protecting the kidneys from tumour lysis syndrome."@en ;
  schema:url <https://onco.cc/drugs/rasburicase/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Rasburicase> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=rasburicase>, <https://www.cancer.gov/about-cancer/treatment/drugs/rasburicase>, <https://www.ema.europa.eu/en/medicines/human/EPAR/fasturtec> ;
  onco:status "approved" ;
  onco:tag "nci-list", "supportive" ;
  onco:modality "Recombinant enzyme (urate oxidase)" ;
  onco:approval "US 2002: Initial management of plasma uric acid in paediatric patients with leukaemia, lymphoma or solid tumours at risk of tumour lysis (adults added 2009)", "EU 2001: Treatment and prophylaxis of acute hyperuricaemia in haematological malignancy with high tumour burden (Fasturtec)" ;
  onco:cancers <https://onco.cc/cancers/all-leukemia/>, <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/cll/> ;
  onco:companies <https://onco.cc/companies/sanofi/> ;
  onco:trials <https://onco.cc/trials/nct00199043/>, <https://onco.cc/trials/nct00057811/>, <https://onco.cc/trials/nct01200485/> .